Hirata K, Hamamoto Y, Ando M, Imamura CK, et al. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II BMC Cancer 2020;20:548.
PMID: 32532230